Chase AIBulk Dataset ExportPricingFAQsBlog
Display currency
Loading news…

Oryzon Genomics SA

ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals.
Barcelona, Catalonia, Spain Founded 2000 11-50 employees For Profit

Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders.

Oryzon Genomics SA on Acquirezy — acquisitions, funding rounds, investments, investors, key people & contacts.

Total Funding
$259.2M
Funding Rounds
26
Last Funding
Acquisitions
1
Monthly Visits
Contacts
20
Ticker
ORY
BME - Madrid Stock Exchange
Patents
86
3 trademarks

About Oryzon Genomics SA

Funding & Financials

Total funding
Funding rounds
Last funding
Last funding type
Last funding date
Funding status
Total equity funding
Revenue range

IPO & Stock

IPO status
Public
Ticker
ORY
Exchange
BME - Madrid Stock Exchange
IPO date
Dec 14, 2015

Web Traffic

Monthly visits
Global traffic rank
6-mo avg visits
Visit duration (s)
Pages / visit
Bounce rate
Rank change (mo)

Technology & IP

Active technologies
3
Active products
12
Patents granted
86
Trademarks
3
Top patent class
Medical Or Veterinary Science; Hygiene
IT spend
$201.82K

Company Info

Founded
2000
Employees
11-50
Operating status
Active
Company type
For Profit
Org types
company
Founders
2
Sub-organizations
1
News articles
95
HQ
Barcelona, Catalonia, Spain
Region
European Union (EU), Europe, Middle East, and Africa (EMEA)
Exit date
Dec 14, 2015

Signals & Scores

Heat score
High
Growth score
Low
Trend (7d)
-0.1
Trend (30d)
7.7
Trend (90d)
7.7
Last leadership hire
Feb 12, 2026

Oryzon Genomics SA Funding Rounds

26 results
Upgrade to Pro to view this datasetUpgrade
Organization NameFunding TypeLead Investor NamesOrg Hq Country
1–5 of 26Show
Page 1 / 6

Oryzon Genomics SA Acquisitions

1 results
Acquiree NameAcquirer NameAcquiree IndustriesAcquiree Hq Country
Crystax Pharmaceuticals2009-03-20Oryzon Genomics SABiotechnologySpain
1–1 of 1Show
Page 1 / 1

Oryzon Genomics SA Key People

Founder and CEO
Global Chief Medical Officer
Director of Business Development
Chief Intellectual Property Officer
Chief Financial Officer
Senior Advisor for Regulatory Affairs
Founder and Shareholder
Chief Scientific Officer
20
professional contacts at Oryzon Genomics SA
Contact execs at Oryzon Genomics SA

Explore 200,000+ acquisitions — free

Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.

Explore all acquisitions
Bulk Dataset Export

Need the data in bulk? Buy the entire dataset.

5.4M company profiles200K+ acquisitions700K+ funding rounds327K investors2M+ people61M contacts45K schools

Delivered as CSV, JSON or Parquet — at startup-friendly pricing.

See bulk export

Recent News related to Oryzon Genomics SA

Loading news…

FAQs about Oryzon Genomics SA

People who checked this page also checked these

Sectors Oryzon Genomics SA invests & acquires in

M&A by year

Browse the full Acquirezy directory.